Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Clinical Oncology|December 6, 2017
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The NetherlandsJohannes J M Kwakman, G Vink, J H Vestjens, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general populationM D Egeler, L V van de Poll-Franse, R Tissier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2014
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trialA J Breugom, W van Gijn, E W Muller, et al.
Immuno-Oncology Technology|July 24, 2024
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanomaI A J van Duin, M Schuiveling, L S Ter Maat, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controlsA H Boekhout, A Rogiers, K Jozwiak, et al.
ESMO Open|December 2, 2021
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugsM G Franken, B Leeneman, M J B Aarts, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2025
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanomaM Bloem, A J M van den Eertwegh, J B A G Haanen, et al.
BMC Cancer|March 26, 2021
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trialE E A P Mulder, K de Joode, S Litière, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2020
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registryM C T van Zeijl, L C de Wreede, A J M van den Eertwegh, et al.
Pageof 5